Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20366 (
substance P
)
21,176
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A functional cellular assay system was developed for the detection of substances modulating the activity of G protein-coupled receptors, linked to the phospholipase C second messenger system. The human adenocarcinoma cell line A549 was transformed with the
Photinus pyralis luciferase
gene under the control of the ICAM-1 gene 5'regulatory region and, subsequently, stably transfected with the human
neurokinin 2
(
NK2
) receptor gene. The ICAM-1 promoter is known to be inducible via the phospholipase C signal transduction pathway. In this
NK2
receptor test cell line, expression of luciferase was inducible by
neurokinin A
and other
NK2
-specific agonists. The order of potency of the three neurokinins
substance P
,
neurokinin A
and neuromedin K was consistent with published data and results from ligand binding studies performed with the same
NK2
test cell line. The agonistic effect of
neurokinin A
could be inhibited in a dose-dependent manner by simultaneous addition of
NK2
-specific antagonists or protein kinase C-inhibitors. Similarly, a stable test cell line expressing the human serotonin 2 receptor was established. Agonist-induced luciferase expression in this cell line was abolished in the presence of 5-HT2-specific antagonists. These cellular assay systems can be employed for the identification of competitive, non-competitive and allosteric modulators of the
NK2
and the 5-HT2 receptor, and they represent prototypes for analogous test cell lines for other phospholipase C-coupled receptors.
...
PMID:Establishment of a cellular assay system for G protein-linked receptors: coupling of human NK2 and 5-HT2 receptors to phospholipase C activates a luciferase reporter gene. 752